Validation of micronuclei frequency in peripheral blood lymphocytes as early cancer risk biomarker in a nested case-control study

Elena Murgia, Michela Ballardin, Stefano Bonassi, Anna Maria Rossi, Roberto Barale

Research output: Contribution to journalArticle

Abstract

Aim of this work was to assess the predictive value of micronuclei (MN) frequency in peripheral blood lymphocytes (PBL) for the risk of cancer death in disease-free individuals. Blood samples from 1650 subjects selected from the general population of Pisa, Italy, were collected between June 1991 and November 1993. The follow-up until January 2005 recorded a total of 111 deaths (52 for cancer). MN frequency was assessed for 49 cancer cases and 101 matched controls. A significantly higher MN frequency was found in cancer cases (4.7 ± 3.4 MN/1000 BN cells) versus controls (1.5 ± 1.7; p <0.0001). Donors were stratified in two classes and multivariate logistic regression analysis confirmed that individuals with high MN frequency (>2.5 MN/1000 BN cells) had a significantly increased risk of cancer death (OR = 10.7; 95% CI = 4.6-24.9; p <0.0001) when compared to individuals with low MN frequency (≤2.5 MN/1000 BN cells). Ageing was associated with a 6% increased risk per year (p = 0.03). No influence of other potential confounders (gender, occupation, smoking and drinking habits) was observed. Finally, subjects with a higher MN frequency showed a higher MR for CVD (Logrank test, p = 0.001). These findings provide strong evidence that MN frequency assessed in PBL of disease-free subjects is a good predictor of cancer death risk, evaluated by a nested case-control study performed 14 years after the original recruitment.

Original languageEnglish
Pages (from-to)27-34
Number of pages8
JournalMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Volume639
Issue number1-2
DOIs
Publication statusPublished - Mar 1 2008

Fingerprint

Tumor Biomarkers
Case-Control Studies
Lymphocytes
Neoplasms
Hematologic Diseases
Occupations
Italy
Drinking
Habits
Smoking
Population

Keywords

  • Biological markers
  • Cancer risk
  • Case-control study
  • Micronucleus test
  • Validation

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Molecular Biology

Cite this

Validation of micronuclei frequency in peripheral blood lymphocytes as early cancer risk biomarker in a nested case-control study. / Murgia, Elena; Ballardin, Michela; Bonassi, Stefano; Rossi, Anna Maria; Barale, Roberto.

In: Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, Vol. 639, No. 1-2, 01.03.2008, p. 27-34.

Research output: Contribution to journalArticle

@article{5ff4212963c2473e9eab2fb4915ecd73,
title = "Validation of micronuclei frequency in peripheral blood lymphocytes as early cancer risk biomarker in a nested case-control study",
abstract = "Aim of this work was to assess the predictive value of micronuclei (MN) frequency in peripheral blood lymphocytes (PBL) for the risk of cancer death in disease-free individuals. Blood samples from 1650 subjects selected from the general population of Pisa, Italy, were collected between June 1991 and November 1993. The follow-up until January 2005 recorded a total of 111 deaths (52 for cancer). MN frequency was assessed for 49 cancer cases and 101 matched controls. A significantly higher MN frequency was found in cancer cases (4.7 ± 3.4 MN/1000 BN cells) versus controls (1.5 ± 1.7; p <0.0001). Donors were stratified in two classes and multivariate logistic regression analysis confirmed that individuals with high MN frequency (>2.5 MN/1000 BN cells) had a significantly increased risk of cancer death (OR = 10.7; 95{\%} CI = 4.6-24.9; p <0.0001) when compared to individuals with low MN frequency (≤2.5 MN/1000 BN cells). Ageing was associated with a 6{\%} increased risk per year (p = 0.03). No influence of other potential confounders (gender, occupation, smoking and drinking habits) was observed. Finally, subjects with a higher MN frequency showed a higher MR for CVD (Logrank test, p = 0.001). These findings provide strong evidence that MN frequency assessed in PBL of disease-free subjects is a good predictor of cancer death risk, evaluated by a nested case-control study performed 14 years after the original recruitment.",
keywords = "Biological markers, Cancer risk, Case-control study, Micronucleus test, Validation",
author = "Elena Murgia and Michela Ballardin and Stefano Bonassi and Rossi, {Anna Maria} and Roberto Barale",
year = "2008",
month = "3",
day = "1",
doi = "10.1016/j.mrfmmm.2007.10.010",
language = "English",
volume = "639",
pages = "27--34",
journal = "Mutation Research",
issn = "0027-5107",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Validation of micronuclei frequency in peripheral blood lymphocytes as early cancer risk biomarker in a nested case-control study

AU - Murgia, Elena

AU - Ballardin, Michela

AU - Bonassi, Stefano

AU - Rossi, Anna Maria

AU - Barale, Roberto

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Aim of this work was to assess the predictive value of micronuclei (MN) frequency in peripheral blood lymphocytes (PBL) for the risk of cancer death in disease-free individuals. Blood samples from 1650 subjects selected from the general population of Pisa, Italy, were collected between June 1991 and November 1993. The follow-up until January 2005 recorded a total of 111 deaths (52 for cancer). MN frequency was assessed for 49 cancer cases and 101 matched controls. A significantly higher MN frequency was found in cancer cases (4.7 ± 3.4 MN/1000 BN cells) versus controls (1.5 ± 1.7; p <0.0001). Donors were stratified in two classes and multivariate logistic regression analysis confirmed that individuals with high MN frequency (>2.5 MN/1000 BN cells) had a significantly increased risk of cancer death (OR = 10.7; 95% CI = 4.6-24.9; p <0.0001) when compared to individuals with low MN frequency (≤2.5 MN/1000 BN cells). Ageing was associated with a 6% increased risk per year (p = 0.03). No influence of other potential confounders (gender, occupation, smoking and drinking habits) was observed. Finally, subjects with a higher MN frequency showed a higher MR for CVD (Logrank test, p = 0.001). These findings provide strong evidence that MN frequency assessed in PBL of disease-free subjects is a good predictor of cancer death risk, evaluated by a nested case-control study performed 14 years after the original recruitment.

AB - Aim of this work was to assess the predictive value of micronuclei (MN) frequency in peripheral blood lymphocytes (PBL) for the risk of cancer death in disease-free individuals. Blood samples from 1650 subjects selected from the general population of Pisa, Italy, were collected between June 1991 and November 1993. The follow-up until January 2005 recorded a total of 111 deaths (52 for cancer). MN frequency was assessed for 49 cancer cases and 101 matched controls. A significantly higher MN frequency was found in cancer cases (4.7 ± 3.4 MN/1000 BN cells) versus controls (1.5 ± 1.7; p <0.0001). Donors were stratified in two classes and multivariate logistic regression analysis confirmed that individuals with high MN frequency (>2.5 MN/1000 BN cells) had a significantly increased risk of cancer death (OR = 10.7; 95% CI = 4.6-24.9; p <0.0001) when compared to individuals with low MN frequency (≤2.5 MN/1000 BN cells). Ageing was associated with a 6% increased risk per year (p = 0.03). No influence of other potential confounders (gender, occupation, smoking and drinking habits) was observed. Finally, subjects with a higher MN frequency showed a higher MR for CVD (Logrank test, p = 0.001). These findings provide strong evidence that MN frequency assessed in PBL of disease-free subjects is a good predictor of cancer death risk, evaluated by a nested case-control study performed 14 years after the original recruitment.

KW - Biological markers

KW - Cancer risk

KW - Case-control study

KW - Micronucleus test

KW - Validation

UR - http://www.scopus.com/inward/record.url?scp=39249083917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39249083917&partnerID=8YFLogxK

U2 - 10.1016/j.mrfmmm.2007.10.010

DO - 10.1016/j.mrfmmm.2007.10.010

M3 - Article

C2 - 18155071

AN - SCOPUS:39249083917

VL - 639

SP - 27

EP - 34

JO - Mutation Research

JF - Mutation Research

SN - 0027-5107

IS - 1-2

ER -